Familial hypercholesterolemia (FH) is characterized by inherited high levels of LDL-C (low-density lipoprotein cholesterol) and premature coronary heart disease. Over a thousand low-frequency variants in LDLR, APOB, and PCSK9 have been implicated in FH, but few have been examined at the population level. We aim to estimate the phenotypic effects of a subset of FH variants on LDL-C and clinical outcomes among 331 107 multiethnic participants.
F amilial hypercholesterolemia (FH) is a common genetic disorder affecting ≈ 1 in 250 adults. 1 The condition causes lifelong elevated levels of LDL-C (low-density lipoprotein cholesterol), which substantially increases the risk for developing atherosclerotic cardiovascular disease, including early onset disease. A recent study suggests that carriers of FH variants have an elevated risk for incident coronary heart disease (CHD) that is independent of a single measure of LDL-C. 2 Treating FH with statins at younger ages can greatly reduce the risk of atherosclerotic cardiovascular disease-related morbidity. 3 Based on the National Institute for Health and Clinical Excellence guideline, 4 FH screening is classified as a tier 1 genomic application. 5 Many causal mutations for FH have been reported, and >1000 variants have been documented in the LDL receptor (LDLR) gene alone. The functional effect of these variants appears to be highly variable, as estimated by LDLR activities and LDL-C in affected families. 6, 7 The advancement of genotyping technologies enables accurate and cost-effective genetic screening of FH variants in large population and assessment of their individual effects. Previously, rare FH variants based on functional annotation were typically grouped together to assess their joint phenotypic effects on LDL-C. 2, 8 The phenotypic effects of most FH variants have been assessed either in pedigrees without proper population controls or in population samples without sufficient sample size to assess phenotypic effects of individual variants. The majority of published genetic studies of FH were conducted in samples of European ancestry (EA). Although the prevalence of FH is higher in samples of African ancestry, 1 the knowledge of FH variants in minority populations is limited. To determine LDL-raising effects, and to better understand the distribution of rare FH variants, we examined pathogenic and likely pathogenic (P/LP) FH variants and their associations with LDL cholesterol levels and clinical outcomes among >300 000 multiethnic veterans in the Million Veteran Program (MVP).
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METHODS
The individual-level data of veteran participants will not be made available to other researchers without approval from the U.S. Department of Veterans Affairs (VA) Institutional Review Board.
Participants of multiple ethnicities were recruited from ≈50 VA healthcare facilities across the United States.
9 Individuals consented to a blood draw and to have their DNA extracted for genomic profiling and linked to their full electronic health record within the VA. Both MVP biobank and this analysis were approved by the VA institutional review boards.
The phenotypic and genotypic measures of the MVP participants were previously described. 10 The detailed methods are available in the Data Supplement.
RESULTS
Among the multiethnic MVP cohort (summarized in Table 1 ), 331 107 veterans (mean age of 58.8 years old; 91.6% male) have both cleaned genotype and phenotype data. The MVP participants represented major continental ancestries of African, European, Asian, and Native American (Figure 1 ). The self-reported Hispanics had heterogeneous genetic background from all major ancestries indicated by the first 2 principal components (Figure 1 ), and because of this and the low number of pathogenic variants in this group, Hispanics were not included in the current analyses.
We identified 58 FH variants classified as P/LP in ClinVar on the MVP biobank array, of which 57 FH variants were not monomorphic ( Table I in the Data Supplement). Although all of these FH variants had at least 1 submission annotated as P/LP, they were classified into 4 clinical significance categories in ClinVar, 4 as pathogenic, 16 as P/LP, 10 as LP, and 27 as conflicting interpretations of pathogenicity. We observed at least 30 carriers for 16 variants (12 variants in LDLR, 2 in APOB, and 2 in PCSK9) which were individually assessed for association with LDL-C ( Table 2 ). The number of carriers observed for the remaining 41 FH variants ranged from 1 to 27. A total of 8 of these 16 P/LP variants, including 5 in LDLR, 2 in APOB, and 1 in PCSK9, were significantly associated with elevated level of maximum LDL-C level over an interval of 15 years (maxLDL) compared with noncarriers after correction for multiple testing (P<0.05/16; Table 2 ). Among these 8 variants, we observed a wide range of effects on the mean max-LDL (+9.4 to +80.2 mg/dL) and a wide range of proportion of individuals with a maxLDL >190 mg/dL (15%-67%; Table 2 ). These effects of individual FH variants were highly heterogeneous (I 2 =97.8%; 95% CI, 97.1%-98.3%; P<0.001). The distribution of max-LDL among carriers of each FH variant was also highly variable ( Figure 2) , with some carriers having maxLDL levels <100 mg/dL. We also observed that variants with the largest effect sizes (eg, rs121908030, rs5742904, rs201573863, and rs151207122) were relatively less common ( Table 2 ). Carriers of the remaining less common variants (<30 carriers for each) collectively demonstrated a mean maxLDL that was increased by 27.3±2.1 mg/dL compared with noncarriers (P=2.8×10 -39 ). We examined the phenotypic effects and distribution of individual P/LP variants among 214 455 MVP participants of EA and 57 850 MVP participants of African ancestry (AA; Table 3 ). Because no single pathogenic variant had sufficient number of carriers (allele count of ≥30) in the MVP Hispanic Americans to assess the genetic effects, we did not include Hispanic Americans in ethnicity-specific analysis. All except one (rs12713559) of the P/LP variants associated with maxLDL had carrier frequencies that were >3-fold difference in prevalence between EA and AA ( Table 3) . One variant in PCSK9 (rs141502002) and 2 variants in LDLR (rs121908030 and rs151207122) were predominantly observed among AA participants, with a frequency >70× greater than that in EA participants. For example, rs121908030 (LDLR), which had the largest effect on maxLDL among all tested P/LP variants, was observed only once among EAs and was 85× more frequent among AA participants than for EA participants.
Including all variants associated with elevated max-LDL (9.4-80.2 mg/dL), we identified 2594 carriers (1 in 128). However, the phenotypic effects of 3 variants, rs141502002 (PCSK9), rs12713559 (APOB), and rs137853964 (LDLR), were moderate (increased max-LDL 9.4-12.6 mg/dL) and not considered as pathogenic for FH in follow-up analyses. Of the remaining variants that increase maxLDL by >20 mg/dL, there were 748 veterans carrying these more deleterious FH variants among 331 107 participants (1 in 443). The 10 most frequent variants accounted for 71.0% of genotyped pathogenic FH variant carriers. The carrier rates of these pathogenic FH variants were 1:462 among 214 455 participants of EA, and 1:362 among 57 850 participants of AA. Among 32 174 individuals with maxLDL above 190 mg/dL, 1 in 117 carried one of pathogenic FH variants. 18.0 chr indicates chromosome; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; maxLDL-C, maximum LDL-C level over an interval of 15 y; and SNP, single nucleotide polymorphism.
We further examined the combined effect of pathogenic FH variants that substantially increase maxLDL (mean increase >20 mg/dL) within each of the 3 FH genes. Carriers of FH variants within LDLR, APOB, and PCSK9 were associated with an increase (>30 mg/dL) of maxLDL (Table 4) . We found the highest mean effect on maxLDL in carriers of APOB FH variants. Carriers of any of these FH variants had a maxLDL that was 36.5±1.4 mg/dL greater than noncarriers (P=1.2×10 -152 ). Ethnicity-specific association analysis revealed that the genespecific and join effects of P/LP variants were similar for individuals of EA and AA (Table 4) .
Overall there were 748 carriers of deleterious FH variants. These individuals had a mean age of 58.5 years old, and 91.7% were male. We determined the collective impact of these deleterious FH variants on a wide range of clinical outcomes through PheWAS (phenomewide association study) by leveraging data from 61.7 million clinical encounters across 3 million patient-years of health data. Among >200 000 participants with EA, we examined 1171 diagnoses within 17 categories of disease based on International Classification of Diseases-Ninth Revision codes. Compared with noncarriers, carriers of FH variants had a statistically significantly (P<0.05/1171 or 4.3×10 -5 ) higher prevalence of clinical diagnoses related to hypercholesterolemia and CHDrelated diagnoses including ischemic heart disease, coronary atherosclerosis, and angina pectoris ( Figure 3) . We further examined the associations between collective FH variants and the prevalence of CHD and peripheral artery disease as determined by a more refined definition of these outcomes leveraging elements of the electronic health record. Adjusted for age, sex, and the top 10 principal components for population structure, FH variants remained collectively associated with a greater prevalence of CHD (odds ratio of 1.68; 95% CI, 1.43-1.97; P=1.65×10 -10 ), but not peripheral artery disease (odds ratio of 1.09; 95% CI, 0.86-1.39; P=0.45). With additional adjustment for maxLDL, the odds ratio for CHD decreased slightly but remained significant (odds ratio of 1.59; 95% CI, 1.36-1.86; P=1.12×10 -8 ). A majority (603 or 80.6%) of the 748 carriers of pathogenic FH variants had been prescribed a statin at least once within the VA healthcare system at any time before or on the day of their enrollment into MVP. Overall the participants who had ever been prescribed statin had mean maxLDL of 186.2 (SD of 56.3) mg/dL, 49.9 mg/dL higher than those without any record of statin prescription. Only 51 (6.8%) had a record of statin use within 90 days before the date of maxLDL measures. A total of 468 -16 ).
To explore the phenotypic effects of other rare variants potentially related to FH, we examined 102 additional variants in APOB, LDLR, and PCSK9 with minor allele frequency <0.01 and minor allele count >30 in the MVP. After correction for multiple testing, we identified 6 variants (3 in APOB and 3 in LDLR) significantly associated with elevated maxLDL (P<0.05/102=4.9×10 -4 ). Carrying each rare allele on average increased 2.5 to 24.6 mg/dL maxLDL among the MVP participants (Table 5 ). Four variants (3 in APOB and 1 in LDLR) coded for missense mutations. Notably, the synonymous variant in LDLR (rs368889457) had the largest effect size (24.6±4.9 mg/dL; P=6.60×10 -7 ) and lowest minor allele frequency (9.44×10 -5 ).
DISCUSSION
The phenotypic expression of FH on LDL-C and the age of onset and severity of disease vary substantially by the causal gene and individual variants. 7, 8, 11, 12 Previous studies have focused on reporting either effects of selected FH variants, pedigrees or case groups without consideration of proper population controls, or compared results to population samples without sufficient sample size to assess individual variants. In this study, we overcame these limitations by analyzing the effect of 57 FH variants annotated as pathogenic among 331 107 subjects receiving care within the VA health care system. We confirmed several low-frequency pathogenic variants raising LDL-C of MVP participants. Among these pathogenic variants, APOB gene on average carried the most severe mutations among 3 tested genes. However, such observation was restricted to the variants measured on the MVP genotyping array. The generalization of the observation to the entirety APOB variants should be cautious and requires complete coverage of genetic mutations in future population studies. We observed notable heterogeneity in the effects of these variants on LDL-C, suggesting the annotation of their pathogenicity is imperfect. Because most P/LP variants for FH have not been validated at a population level, concluding pathogenicity on the basis of a variant's putative disruption of the gene's function or its protein product may be insufficient.
We investigated the distribution of FH variants among participants of EA (n=214 455) and AA (n=57 850) separately to address the limited knowledge of FH variant distribution among AAs in comparison to EAs. 13 We found that all except one P/LP variants associated with maxLDL had carrier frequencies that were >3-fold different between the EA and AA. Several variants, including the one with the largest effect on maxLDL among all tested P/LP variants (rs121908030 of LDLR), were predominantly observed among AAs. Additionally, the joint carrier frequency of deleterious FH variants in AA (1:362) is also higher than that in EA (1:462). Such differences in FH variant distribution between races demand in-depth genotyping efforts to discover and validate FH variants and other rare pathogenic variants among large multiethnic populations.
The current estimated prevalence of FH is ≈1:250 in the United States 1 and other Western countries. [14] [15] [16] [17] Recent exome-sequencing based screenings have reported frequencies for FH carriers of 1:222 8 and 1:211 2 in an electronic health record-based cohort and a coronary artery disease case-control population, respectively. However, the latter study included only 7% of African ancestry. In this multiethnic study, the calculated FH carrier frequency was dependent on the inclusion and exclusion criteria of individual variants and race/ethnicity. The overall results were substantially influenced by a few common variants. When 3 variants with moderate LDL-raising effects were included, the FH carrier frequencies were 1:128, 1:234, and 1:50 among all, European American alone, and African American alone participants, respectively. Notably, the FH carrier frequency among European Americans is consistent with previous studies (1:211) that included up to 7% of African Ancestry.
2 A single variant rs141502002 (PSCK9), which is associated with moderately increased maxLDL (9.4±1.1 mg/dL, P=3.7×10 -17 ) was predominantly observed among AA and accounted for 81% of LDL-raising FH variant carriers in this ethnic group. After excluding the 3 variants with moderate effects on max-LDL, we estimated a lower FH carrier frequency (1:443) using a more stringent inclusion criteria of LDL-raising FH variants (mean increase >20 mg/dL) in this microarray-based genotyping study.
Using a PheWAS approach, we explored the phenotypic effects of FH variants for >1000 clinical diagnoses in the electronic health record. We identified that FH variant carriers with elevated risk for diagnoses related to CHD or hypercholesterolemia, but no obvious pleiotropic effects on other clinical diagnosis. Although we assembled one of the largest samples of FH carriers, the number of some less frequent clinical diagnoses may partially explain why we did not observe strong pleiotropic effect of FH variants on other disease outcomes. Using refined phenotyping algorithms of CHD and peripheral artery disease, we confirmed the genetic association with CHD with and without adjustment of maxLDL, but not with peripheral artery disease. Because FH carriers in the MVP achieved comparable LDL-C to noncarriers after statin treatment, the residual risk for CHD adjusted for maxLDL suggests that earlier and more aggressive treatments may be needed to further reduce the CHD risk among FH carriers.
Our study has several important limitations. First, our genotyping platform limited the assessment of the phenotypic effects of FH variants genotyped on the MVP biobank array but did not include all documented FH variants. However, the number of identified carriers with moderate to more severe form of FH variants should account for a large proportion of all deleterious FH variants, most having extremely low frequency in the population. Large-scale sequencing studies may ultimately be necessary to provide complete identification of FH variants in multiethnic populations. Second, our study included predominantly male veterans (<10% women) over the age of 50 years, which is not representative of the general population. Future larger-scale genomic studies of FH need to cover broader demographics, especially younger participants, 18 because severe FH often leads to greater cardiovascular disease risk in young-and middle-aged adults. Lastly, the older age of MVP participants may introduce ascertainment bias by not including individuals with more severe clinical outcomes (eg, death) at a younger age. Although we were not able to quantify such bias using available data, such a loss of severe FH patients may have resulted in an observed phenotypic effect of ≥1 FH variants that is lower than the true overall effect of that variant on LDL-C.
Both genetic and environmental factors can potentially modify the effects of FH variants on LDL-C. Because there were no previous reports of such gene-gene or gene-environment interactions for FH pathogenicity, we assumed the independence between pathogenic variants and other genetic (eg, protective variants) or environmental factors in present study. Other molecular factors such as lipoprotein (a) may also influence the genetic effects of FH variants, particularly in regards to race differences. Because lipoprotein (a) was not systematically measured, we did not examine its influence on FH variants in present study.
FH patients have elevated LDL-C throughout life but are underdiagnosed and undertreated in the general population. Effective treatment to reduce the risk of developing atherosclerotic diseases requires timely diagnosis at the youngest age possible. Universal screening through gene sequencing has the potential to identify all individuals with FH but is not yet feasible or cost effective. Because FH is an autosomal dominant disorder, targeted screening (eg, cascade screening 19 and child-parent screening 20, 21 ) among the family members of index cases may be more efficient. Positive genotyping of pathogenic FH variants is often used as a critical component of the diagnosis. 18, 22, 23 The precision of a genetic diagnosis depends on accurate annotation of pathogenicity. Our findings of heterogeneous phenotypic effects within and across individual FH variants highlight the limitations in the ability to correctly classify the pathogenicity of many of these variants hindering a clinician's optimal interpretation and application of the results of genetic tests for FH. Given the wide range of individual FH variants' effects on LDL-C, we suggest including additional components of the evidence to better annotate the pathogenicity in current databases, such as ClinVar. Such annotation components should add the summary statistics from family-based or population-based studies of individual disease-causing variants to assist the researchers to accurately assess and rank the evidence of pathogenicity beyond putatively functional changes. Broadly, we recommend extra caution when interpreting the potential effect on LDL-C of a purported FH variant that has not been examined in large-scale population studies. This extra caution includes the search for additional evidence of pathogenicity through the careful documentation of a family history of hyperlipidemia and CHD. Importantly, both cholesterol-based and genotype-based testing for the diagnosis of FH should continue to be used. 24 Among individuals with no family history or other pathognomonic clinical signs of FH, cholesterol level may serve as a primary testing, with gene testing adding to cardiovascular disease risk prediction in certain individuals carrying validated pathogenic variants.
ARTICLE INFORMATION
